AuntMinnie.com staff writersAIRoche to collaborate with Ibex Medical Analytics, AmazonRoche plans to collaborate with Ibex Medical Analytics and Amazon Web Services to make Ibex's decision-support tools accessible to pathology labs.October 26, 2023CTAnnalise.ai receives FDA clearance for radiology triage deviceAnnalise.ai has secured 510(k) clearance from the FDA for its triaging and notification of obstructive hydrocephalus on noncontrast brain CT scan software.September 12, 2023Industry NewsRSNA launches series of radiology-focused business reportsThe RSNA is launching "RSNA Market Insights," a series of radiology-focused business reports that offer key insights from radiologists.September 11, 2023AIFDA clears Qure.ai's AI chest x-ray softwareThe U.S. Food and Drug Administration (FDA) has cleared Qure.ai's AI-powered qXR chest x-ray software.September 11, 2023BreastAir pollution tied to breast cancer incidenceResearchers at the National Institutes of Health (NIH) have found that high levels of particulate air pollution are tied to increased breast cancer incidence.September 11, 2023CTThirona secures financing for AI CT techAI thoracic CT developer Thirona has secured 7.5 million euros ($8 million U.S.) in funding for further development of its AI CT technology.September 11, 2023CTKromek highlights Spectrum's integration of its detectorsRadiation technology developer Kromek Group is highlighting that Spectrum Dynamics Medical has introduced Veriton-CT 300, which incorporated Kromek's digital detectors.September 11, 2023CTFDA clears Xeos Aura 10 PET-CT specimen imaging systemThe U.S. Food and Drug Administration (FDA) has approved Xeos' Aura 10 PET-CT specimen imaging system for the operating room.September 10, 2023Nuclear MedicineEczacıbaşı-Monrol to expand Lu-177 productionTurkish radiopharmaceutical company Eczacıbaşı-Monrol plans to expand its Lutetium-177 (Lu-177) production capacity.September 10, 2023Radiation Oncology/TherapyBlue Earth highlights prostate cancer preclinical resultsBlue Earth Therapeutics is highlighting results from a preclinical study evaluating the efficacy of Ac-225 rhPSMA-10.1 compared with Lu-177 rhPSMA-10.1 for the treatment of prostate cancer.September 10, 2023Page 1 of 3774Next PageTop StoriesMolecular ImagingSNMMI: Retreatment with Lu-177 PSMA-617 shows promise in mCRPC patientsRetreatment with Lu-177 PSMA-617 is emerging as a potential approach in men with prostate cancer.Nuclear MedicineSNMMI: New PET tracers developed for imaging brain disordersMolecular ImagingSNMMI: SPECT/CT valuable after Lu-177 therapyWomens ImagingDL model improves detection of breast arterial calcificationsSponsor ContentJoin Us June 26 at 12 Noon ET for a FREE webinar!
